Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Daiichinkyo CoDSKYF 79 3-Year EBITDA Growth Rate is 21.20% as of Jun. 2026, which is 1919% above its 10-year median of 1.05. GuruFocus rates DSKYF with a GF Score™ of 79/100 and a GF Value™ of $31.66 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 808 Drug Manufacturers companies, Daiichinkyo Co ranks better than 70.17% on this metric.
During the past 12 months, Daiichinkyo Co's average EBITDA Per Share Growth Rate was -19.10% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 21.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 29.00% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 11.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Daiichinkyo Co was 47.50% per year. The lowest was -14.30% per year. And the median was 1.05% per year.
Daiichinkyo Co (OTCPK:DSKYF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Daiichinkyo Co 3-Year EBITDA Growth Rate Related Terms
DSKYF vs LLY, JNJ, ABBV: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - General subindustry, Daiichinkyo Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daiichinkyo Co 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Daiichinkyo Co's 3-Year EBITDA Growth Rate falls into.
Daiichinkyo Co 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 21.20% mean?
Daiichinkyo Co (DSKYF) has a 3-Year EBITDA Growth Rate of 21.20% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Daiichinkyo Co and its competitors. This is 1919% above median its historical median of 1.05. According to the industry distribution chart, Daiichinkyo Co ranks #241 out of 808 companies in the Drug Manufacturers industry, placing it in the top 29.8%.
Is Daiichinkyo Co's 3-Year EBITDA Growth Rate too high?
Daiichinkyo Co's current 3-Year EBITDA Growth Rate of 21.20% is 1919% above median its 10-year median of 1.05. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Daiichinkyo Co's value of 21.20% is 138.2% above this industry median. Based on the distribution chart, Daiichinkyo Co ranks #241 out of 808 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Daiichinkyo Co has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Daiichinkyo Co's 3-Year EBITDA Growth Rate compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Daiichinkyo Co ranks #241 out of 808 companies for 3-Year EBITDA Growth Rate. This puts Daiichinkyo Co in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Daiichinkyo Co's value of 21.20% is 138.2% above this benchmark. While the company's 10-year median is 1.05 vs. the industry median of 8.90, Daiichinkyo Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Daiichinkyo Co's current 3-Year EBITDA Growth Rate of 21.20% is 138.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Daiichinkyo Co and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daiichinkyo Co's current 3-Year EBITDA Growth Rate is 21.20%, which is 1919% above median its own 10-year median of 1.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daiichinkyo Co stock overvalued right now?
Based on GuruFocus' analysis, Daiichinkyo Co (DSKYF) is currently considered Significantly Undervalued. The stock's GF Value™ is $31.66, compared to a current price of $18.34 — trading 42.1% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 21.20%, which is 1919% above median its 10-year median of 1.05 and 138.2% above the Drug Manufacturers industry median of 8.90. Daiichinkyo Co's overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Daiichinkyo Co (DSKYF), the current 3-Year EBITDA Growth Rate is 21.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Daiichinkyo Co (DSKYF) Overvalued in 2026?
Based on GuruFocus' analysis, Daiichinkyo Co stock appears to be undervalued.
The current stock price of $18.34 is trading 42.1% below its estimated GF Value™ of $31.66.
GuruFocus considers Daiichinkyo Co to be Significantly Undervalued.
Key valuation signals for DSKYF:
3-Year EBITDA Growth Rate: 21.20% (1919% above median its 10-year median of 1.05)
GF Value™: $31.66 vs. price of $18.34 (42.1% below fair value)
Industry Position: 138.2% above the Drug Manufacturers median (#241 of 808)
No single metric tells the full story. See the DSKYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu was first approved in the US in December 2019, and Datroway was first approved in January 2025.
79GF Score
Get the complete analysis for DSKYF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DSKYF has been successfully added to your 
